Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine.

Depression and anxiety - 1 Jan 2000

Ereshefsky L, Dugan D

Abstract excerpt

Improving outcomes for patients with depression involves selecting the best possible drug therapy. Considerations relevant to drug product selection include: 1) pharmacokinetic issues such as half-life and time to steady-state, and protein binding; 2) pharmacodynamic drug-drug interactions; and 3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclohexanols
Share to Cytochrome P-450 Enzyme System
Share to Depressive Disorder

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Drug Tolerance

Share to Half-Life

Share to Selective Serotonin Reuptake Inhibitors

Share to Venlafaxine Hydrochloride

Source

Identifiers

PMID: 11098412
DOI: 10.1002/1520-6394(2000)12:1+<30::aid-da4>3.0.co;2-g

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-11098412-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine.PMID 11098412Read ↗

CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine: Results from a Population Pharmacokinetic Model in Older Adults with Depression.Semantic proximity Read ↗

Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms.Semantic proximity Read ↗

An observational study of Venlafaxine and CYP2D6 in clinical practice.Semantic proximity Read ↗

Doxepin Drug-Drug and Drug-Gene Interactions: Clinical Implications and Mechanistic InsightsSemantic proximity Read ↗

PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine.Semantic proximity Read ↗

Influence of combined CYP2C19 and CYP2D6 phenotypes on adverse drug reactions in patients with major depressive disorder: a clinical cohort studySemantic proximity Read ↗

Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.Semantic proximity Read ↗

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.Semantic proximity Read ↗

A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir.Semantic proximity Read ↗

Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder.Semantic proximity Read ↗

Influence of combined CYP2C19 and CYP2D6 phenotypes on adverse drug reactions in patients with major depressive disorder: a clinical cohort study.Semantic proximity Read ↗

Pharmacogenetics and the pharmacological management of depression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.